2013
DOI: 10.1128/jcm.00863-13
|View full text |Cite
|
Sign up to set email alerts
|

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

Abstract: Isavuconazole is a new broad-spectrum triazole with a favorable pharmacokinetic and safety profile. We report the MIC distributions for isavuconazole and 111 isolates of Candida (42 Candida albicans, 25 Candida glabrata, 22 Candida parapsilosis, 14 Candida tropicalis, and 8 Candida krusei isolates), as determined by Clinical and Laboratory Standards Institute (CLSI) and European Committee on Antimicrobial Susceptibility Testing (EUCAST) broth microdilution (BMD) methods. Also, the relative activities of isavuc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

7
58
1
1

Year Published

2013
2013
2019
2019

Publication Types

Select...
10

Relationship

0
10

Authors

Journals

citations
Cited by 80 publications
(67 citation statements)
references
References 37 publications
(54 reference statements)
7
58
1
1
Order By: Relevance
“…Thus, some of the isolates we receive for susceptibility testing may be more likely to be non-wild-type strains. However, the overall MIC distributions from our study shown in Table 3 are similar to those reported by others, including those from large surveillance studies (6,7,17). The results from our laboratory demonstrate that the rates of resistance for the echinocandins and the azoles may be increased with the use of the new CLSI antifungal breakpoints.…”
supporting
confidence: 77%
“…Thus, some of the isolates we receive for susceptibility testing may be more likely to be non-wild-type strains. However, the overall MIC distributions from our study shown in Table 3 are similar to those reported by others, including those from large surveillance studies (6,7,17). The results from our laboratory demonstrate that the rates of resistance for the echinocandins and the azoles may be increased with the use of the new CLSI antifungal breakpoints.…”
supporting
confidence: 77%
“…Isavuconazole in vitro demonstrates superior hyphal growth inhibition and MICs against Aspergillus fumigatus in comparison to those of voriconazole (10)(11)(12)(13)(14). However, there is a paucity of laboratory animal data for isavuconazole against Aspergillus spp.…”
mentioning
confidence: 98%
“…Isavuconazole action includes in vitro activity against Aspergillus and Candida species, although the susceptibility of few clinical isolates has been studied (7)(8)(9)(10)(11)(12)(13). Epidemiological cutoff (ECOFF) values can assist in identifying isolates with raised MICs and/or a greater risk of the presence of a mechanism of resistance.…”
mentioning
confidence: 99%